EntertainmentMicroneedling patch shows promise in tackling alopecia areata

Microneedling patch shows promise in tackling alopecia areata

Scientists have developed a microneedle patch that could revolutionise the treatment of alopecia areata. The new method delivers immunoregulatory molecules directly to the skin and has shown promising results in hair regeneration and inflammation reduction.

Breakthrough in the treatment of alopecia areata
Breakthrough in the treatment of alopecia areata
Images source: © Canva
Konrad Siwik

25 June 2024 10:13

The new method, developed by MIT, Brigham and Women's Hospital, and Harvard Medical School scientists, could significantly change the approach to treating alopecia areata. Thanks to the innovative microneedle patch, which delivers immunoregulatory molecules directly to the skin, researchers have achieved promising results in hair regeneration and inflammation reduction.

Alopecia areata, also known as alopecia areata, is an autoimmune skin disorder in which the immune system attacks hair follicles, leading to their weakening and hair loss. It affects people worldwide at different ages, causing not only hair loss but also negatively impacting their mental health and self-esteem.

How does the microneedling patch work?

The new approach to treating alopecia areata uses a microneedling patch that delivers therapeutic molecules directly to the skin. Microneedling is a technique that involves creating microscopic punctures in the skin that allow for deeper penetration of medicinal substances. In this case, molecules that modulate the activity of T lymphocytes, critical immune cells responsible for attacking hair follicles, are used.

Research conducted on mice showed that the patch not only effectively reduces inflammation in the skin but also stimulates hair regrowth. Mice to which the patch was applied showed significant improvement compared to the control group, suggesting that the therapy may be a promising solution for people suffering from alopecia areata.

A man suffering from alopecia areata
A man suffering from alopecia areata© Canva

Potential applications in other autoimmune diseases

Although the research focuses on alopecia areata, scientists see potential for this technology in treating other autoimmune skin diseases such as vitiligo and psoriasis. Vitiligo is a condition in which the immune system attacks melanocytes, the cells that produce skin pigment, forming white patches. On the other hand, Psoriasis is characterised by excessive skin cell proliferation and inflammation. In both cases, modulating the immune response may bring therapeutic benefits.

The discovery of the microneedle patch as a tool for delivering immunoregulatory molecules opens new possibilities in treating autoimmune diseases. The research team plans to conduct further studies to understand the patch's mechanisms and optimise its effectiveness. The next step will be conducting clinical trials on humans, which will allow for the assessment of the therapy's safety and efficacy in real-world conditions.

A woman suffering from alopecia areata
A woman suffering from alopecia areata© Canva

Significance for patients suffering from alopecia areata

The new discovery could significantly improve the quality of life for people suffering from alopecia areata. Hair loss often comes with lowered self-esteem and emotional problems. Effective therapy that allows for hair regrowth can improve patients' mental and social well-being.

The microneedle patch offers hope for a safe and effective solution that can be used at home without frequent doctor visits. If further studies confirm its effectiveness, the new treatment method could become widely available and affordable for patients worldwide.

Related content
© Daily Wrap
·

Downloading, reproduction, storage, or any other use of content available on this website—regardless of its nature and form of expression (in particular, but not limited to verbal, verbal-musical, musical, audiovisual, audio, textual, graphic, and the data and information contained therein, databases and the data contained therein) and its form (e.g., literary, journalistic, scientific, cartographic, computer programs, visual arts, photographic)—requires prior and explicit consent from Wirtualna Polska Media Spółka Akcyjna, headquartered in Warsaw, the owner of this website, regardless of the method of exploration and the technique used (manual or automated, including the use of machine learning or artificial intelligence programs). The above restriction does not apply solely to facilitate their search by internet search engines and uses within contractual relations or permitted use as specified by applicable law.Detailed information regarding this notice can be found  here.